At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 104 enrolled
Drug / intervention
Opdivo +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating Opdivo and Yervoy for Renal Cell Carcinoma. Completed, enrolled 104 participants across 11 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate safety and efficacy of different administration regimens of nivolumab plus ipilimumab in subjects with renal cell carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
CountriesAustralia, Chile, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 2017
Enrollment StartFeb 2017
Primary CompletionNov 2017
Study CompletionJun 2021
TodayJul 2026
First PostedJan 24, 2017
Enrollment StartFeb 16, 2017
Primary CompletionNov 27, 2017
Study CompletionJun 15, 2021
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 9.4 years ago
Interventions
Opdivobiological
Specified dose on specified days
Yervoybiological
Specified dose on specified days